An amyloidosis diagnosis can take upwards of 2 years.Initial symptoms often are nondescript, and irreversible organ damage frequently occurs before disease confirmation.

(Boston) — AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow ...

LOS ANGELES, CA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical ...

AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...

Biologically optimised plasma p-tau217 cutoffs improve amyloid beta detection accuracy and cost efficiency. Learn more about the study.

Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate “I ...

LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (IMMX) (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage ...

The American Society of Hematology (ASH) released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening disease of the bone marrow. The guidelines, published in the ...

This one-hour on-demand video learning module features a panel of expert multidisciplinary providers who specialize in the treatment of ATTR (Transthyretin) Amyloidosis. Their discussion includes a ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A light chain depleter antibody, anselamimab was being investigated in ...

ZURICH, Dec. 4, 2025 /PRNewswire/ -- Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by ...